MIFH
NKTR icon

Migdal Insurance & Financial Holdings’s Nektar Therapeutics NKTR Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-82
Closed -$75K – 781
2018
Q3 		$75K Buy
82
+51
+165% +$43.5K ﹤0.01% 623
2018
Q2 		$23K Buy
31
+30
+3,000% +$34.6K ﹤0.01% 710
2018
Q1 		$2K Buy
+1
New +$1.29K ﹤0.01% 614

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Migdal Insurance & Financial Holdings's NKTR Position: Q4 2018 in Review

Migdal Insurance & Financial Holdings sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 82 shares — an estimated $75K sold.

Migdal Insurance & Financial Holdings first reported a position in NKTR in Q1 2018 and held it in 3 quarters. The position peaked at $75K in Q3 2018. 343 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Migdal Insurance & Financial Holdings reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 82 Nektar Therapeutics shares in Q4 2018, an estimated $75K.
  • Migdal Insurance & Financial Holdings first reported a position in Nektar Therapeutics in Q1 2018 and held it in 3 quarters.
  • Migdal Insurance & Financial Holdings's Nektar Therapeutics position peaked at $75K in Q3 2018.
  • 343 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q4 2018, filed 13 Feb 2019.